NEW YORK, September 11, 2025--(BUSINESS WIRE)--Tema ETFs ("Tema"), the New York-based provider of innovative exchange traded funds (ETFs), today announced the launch of the Tema International Durable ...
DRI to assist in advancing potential of iTOL-100 to enable engraftment and long-term survival of transplanted insulin producing stem cells without the use of chronic immunosuppression Pre-clinical ...
Kadimastem Ltd. and Itolerance Inc. have held a type B pre-IND meeting with the FDA regarding the development of ITOL-102, an investigational biologic for the treatment and potential cure of type 1 ...
NLS Pharmaceutics Ltd. (Nasdaq: NLSP”) (“NLS”) and Kadimastem Ltd. (“Kadimastem”), a clinical-stage company specializing in "off-the-shelf" allogeneic cell therapy products for neurodegenerative ...
iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases. Manufacturing agreement supports advancement of iTolerance ...
ITOL ETF Stock Price History Assess comprehensive historical stock price data for ITOL. This dataset provides a wealth of information, including the closing price, opening price, highest and lowest ...
Company leveraging iTOL-100 to advance a pipeline of programs that have the potential to cure diseases, such as Type 1 Diabetes, without the need for life-long immunosuppression MIAMI, FL / ACCESSWIRE ...
Access the complete ITOL share price history for the Tema International Durable Quality ETF, including opening and closing prices, daily highs and lows, and percentage changes. The interactive chart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results